Onxeo Sa Stock Earnings Per Share
| C4X Stock | 0.07 0.0008 1.16% |
Onxeo SA fundamentals help investors to digest information that contributes to Onxeo SA's financial success or failures. It also enables traders to predict the movement of Onxeo Stock. The fundamental analysis module provides a way to measure Onxeo SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Onxeo SA stock.
Onxeo |
Onxeo SA Company Earnings Per Share Analysis
Onxeo SA's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Onxeo SA has an Earnings Per Share of 0.0 times. This indicator is about the same for the average (which is currently at 0.0) sector and about the same as Earnings Per Share (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
Onxeo Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onxeo SA's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onxeo SA could also be used in its relative valuation, which is a method of valuing Onxeo SA by comparing valuation metrics of similar companies.Onxeo SA is currently under evaluation in earnings per share category among its peers.
Onxeo Fundamentals
| Current Valuation | 5.01 M | |||
| Price To Book | 0.46 X | |||
| Price To Sales | 4.31 X | |||
| Total Debt | 9.91 M | |||
| Market Capitalization | 46.31 M | |||
| Total Asset | 53.06 M | |||
| Z Score | 2.4 | |||
| Net Asset | 53.06 M |
About Onxeo SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onxeo SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onxeo SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onxeo SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Onxeo Stock Analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.